 |
|
|
| |
Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: preliminary results from the phase 2 SOLSTICE trial in non-cirrhotic and compensated cirrhotic participants
|
| |
| |
European Association for the Study of the Liver (EASL ) Congress; 8 June 2024; Milan, Italy.
Tarik Asselah,1 Anca Streinu-Cercel,2 Alina Jucov,3 Ed Gane,4 Heiner Wedemeyer,5 Pietro Lampertico,6,7 Michael A Chattergoon,8
Pan Wu,8 Sonia Maciejewski,8 Cara Pilowa,8 Afshar Hassani,8 Todd Correll,8 Carey Hwang,8 Kosh Agarwal9
|
| |
|
|
|
|
|
